Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness SummitBusiness Wire • 02/20/25
Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid GelsBusiness Wire • 02/13/25
Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?Zacks Investment Research • 01/22/25
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's WhyInvestors Business Daily • 01/21/25
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's GuidanceBusiness Wire • 01/21/25
Here's Why Evolus (EOLS) Could be Great Choice for a Bottom FisherZacks Investment Research • 11/18/24
Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS)Zacks Investment Research • 11/14/24
Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device RegulationBusiness Wire • 10/31/24
Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled ConsumersBusiness Wire • 10/29/24
Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024Business Wire • 09/06/24
Evolus reports first-ever adjusted profit in Q2 fueled by strong sales of Botox rivalReuters • 07/31/24
Evolus, A Medical Aesthetics Player, Becomes Profitable — Two Quarters EarlyInvestors Business Daily • 07/31/24
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue GuidanceBusiness Wire • 07/31/24